Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.51 USD | -1.06% | -3.65% | -7.00% |
05-17 | HC Wainwright Adjusts Kala Pharmaceuticals Price Target to $18 From $21, Maintains Buy Rating | MT |
04-02 | HC Wainwright Trims KALA BIO's Price Target to $21 From $22, Keeps Buy Rating | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-7.00% | 18.34M | |
+37.74% | 723B | |
+34.38% | 595B | |
-2.07% | 369B | |
+20.25% | 332B | |
+2.99% | 282B | |
+17.11% | 244B | |
+9.71% | 208B | |
-4.66% | 205B | |
+2.81% | 168B |
- Stock Market
- Equities
- KALA Stock
- News KALA BIO, Inc.
- Transcript : Kala Pharmaceuticals, Inc. Presents at BofA Securities 2020 Health Care Conference, May-13-2020 04